Poland
· Delayed Price · Currency is PLN Molecure Company Description
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.
The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH.
It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022.
Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
| Country | Poland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Marcin Szumowski |
Contact Details
Address: Zwirki i Wigury 101 Warsaw, 02-089 Poland | |
| Phone | 48 225 52 67 24 |
| Website | molecure.com |
Stock Details
| Ticker Symbol | MOC |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLONCTH00011 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marcin Szumowski | Chief Executive Officer |
| Slawomir Broniarek | Chief Financial Officer |